The present disclosure relates to a use of virus-like particles including Toxoplasma gondii apical membrane antigen 1 for serodiagnosing toxoplasmosis, wherein an enzyme-linked immunosorbent assay with an infected serum was conducted using virus-like particles expressing Toxoplasma gondii AMA1, and higher sensitivity than the existing Toxoplasma gondii antigen was observed using virus-like particles, and no false diagnosis such as false negatives and false positives appeared after a reaction with a malaria-infected serum and thus high specificity was identified.

The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.

The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.

Embodiments are directed to diagnostic devices based on surface-enhanced Raman scattering comprising: an inlet module receiving liquid to be analyzed; a reaction module having a first region arranged with a receiving hole and a second region arranged with an output hole, wherein the receiving hole is communicated with the output hole through a flow channel configured with at least one chemical set, the reaction module receives the liquid delivered by the inlet module via the receiving hole, and the liquid to be analyzed flows through the chemical sets placed in the flow channel to obtain nanoparticles-carrying liquid, and the nanoparticles-carrying liquid configured to flow into the second region of the reaction module; and a detection module receiving the nanoparticle-carrying liquid from the output hole of the reaction module.

The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.

A system, method, apparatus and diagnostic test for Plasmodium vivax, to determine a likelihood of a specific timing of infection by P. vivax in a subject, and hence identify individuals with a high probability of being infected with otherwise undetectable liver-stage hypnozoites. The system, method, apparatus and diagnostic test relate to the identification of hypnozoites (“dormant” liver-stages), or at least of the likelihood of the subject being so infected. Optionally and preferably, the specific timing relates to recent infections, for example within the last 9 months.

A method is provided that includes rinsing an oral cavity of a subject with a rinse liquid. Thereafter, a gargle liquid is introduced into the oral cavity and gargled by the subject. Thereafter, at least a portion of the gargled liquid is collected as a specimen sample. Other embodiments are also described.

Identification of immunodominant Babesia microti antigens using genome-wide immunoscreening is described. Candidate antigens were screened against sera from patients with clinical babesiosis. Also described are diagnostic assays with high sensitivity and specificity for detecting B. microti-specific antibodies in patient samples using the identified immunodominant antigens.

In various embodiments nanoparticle drug delivery vehicles are provided that specifically deliver a cargo to a target pathogenic organism. In certain embodiments the drug delivery vehicle comprises a mesoporous silica nanoparticle comprising a plurality of pores and an outer surface through which the pores are disposed; a cargo disposed in the pores; one or more antigens attached to the surface of the nanoparticle; an antibody that specifically binds the antigens and are bound to the antigens, wherein the antibody inhibits diffusion of the cargo out of the pores and permit release of the cargo when the drug delivery vehicle is in the presence of the antigen or a pathogen displaying the antigen.

The present disclosure relates to the field of immunology, in particular to a B-cell epitope of Trichinella spiralis cysteine protease inhibitor, a hybridoma cell line, a monoclonal antibody and uses thereof. The present disclosure provides a hybridoma cell line that can generate anti-WN10 antibody, and identifies the specific B-cell epitope of WN10 protein recognized by the monoclonal antibody. These are of great significance for the diagnosis of trichinellosis, for the establishment of competitive ELISA for detecting antibodies and sandwich ELSIA for detecting circulating antigens, for the detection of Trichinella spiralis in different hosts and for the development of subunit vaccines.